- Home
- LXRX vs NATH Comparison
LXRX vs NATH Comparison
Compare LXRX & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | NATH |
|---|---|---|
| Founded | 1995 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.0M | 397.6M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXRX | NATH |
|---|---|---|
| Price | $1.14 | $94.58 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.23 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 42.8K |
| Earning Date | 11-06-2025 | 02-05-2026 |
| Dividend Yield | N/A | ★ 2.14% |
| EPS Growth | N/A | ★ 4.02 |
| EPS | N/A | ★ 5.56 |
| Revenue | $70,864,000.00 | ★ $154,991,000.00 |
| Revenue This Year | $56.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.84 |
| Revenue Growth | ★ 1255.21 | 7.82 |
| 52 Week Low | $0.28 | $75.15 |
| 52 Week High | $1.66 | $118.50 |
Technical Indicators
Market Signals| Indicator | LXRX | NATH |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 44.30 |
| Support Level | $1.12 | $92.81 |
| Resistance Level | $1.24 | $95.54 |
| Average True Range (ATR) | 0.07 | 2.23 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 8.17 | 24.92 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.